Anchiano Appoints Stan Polovets as Chairman of the Board
Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”) recently announced that Mr. Stan Polovets has been elected chairman of its board of directors. Mr. Polovets joined the
Gamida Cell Adds David Fox to Board of Directors
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced that David
JLM Immuno-Oncology Company Nectin raises $6m from Amoon
Nectin Therapeutics is developing a number of antibodies that can enhance the treatments being offered to cancer patients. Jerusalem immuno-oncology biotherapies company Nectin Therapeutics has
Atox Bio’s Reltecimod Effective in Phase 3 Clinical Trials against Flesh Eating Disease
Reltecimod is Atox Bio‘s lead product in development and is currently in late stage clinical trials for Necrotizing Soft Tissue Infections (NSTI) (Flesh Eating Disease)
US FDA OKs Immunovative Therapies Universal Anti-Viral Vaccine Phase I/II Clinical Trial for Elderly
Immunovative Therapies‘ universal vaccine is designed to protect elderly adults from all respiratory viral infections, including COVID-19, influenza and any future mutations or novel viral
BiondVax’s M-001 Universal Influenza Vaccine Completes Successful NIH Phase 2 Clinical Trial
The NIAID of the NIH completed the Clinical Study Report (CSR) of a Phase 2 clinical trial of the BiondVax’s M-001 universal influenza vaccine candidate.
Betalin Therapeutics Awarded funding from Fast Track to Innovation (FTI) of the Horizon 2020 program
The funding award to Betalin Therapeutics along with their partners from Dresden and Zurich was just announced. The demand for diabetes drugs keeps increasing as
Silkim Pharma’s New Drug Against Coronavirus Receives Response from FDA in Record Time!!
On April 22nd, Silkim Pharma filed a pre-Investigational New Drug (PIND) meeting request with the U.S. Food and Drug Administration (FDA) for its drug candidate
Gamida Cell Hits Goal in Phase 3 Blood Cancer Trial
Gamida Cell Ltd (Nasdaq: GMDA) is an advanced cell therapy company that uses umbilical cord blood, a rich source of stem cells, to find cures
